Researchers at the Mayo Clinic have developed milk-derived nanoparticles capable of delivering gene-therapy payloads directly to cholangiocarcinoma tumors [1].
This development targets a rare and aggressive form of bile duct cancer that currently has limited treatment options. By improving the precision of therapy delivery, the platform aims to increase the effectiveness of aggressive treatments for patients with this disease [2].
The research, based in Rochester, Minnesota, utilizes a nanoparticle platform to navigate the body and deposit therapeutic agents into the malignant cells [1]. Cholangiocarcinoma is known for its resilience against standard therapies, making targeted delivery a critical hurdle for oncologists [2].
Dr. Rory Smoot, a surgical oncologist at the Mayo Clinic, is among the researchers working on the project [1]. The effort involves collaboration with patient advocates, including Melinda Bachini, the chief patient officer of the Cholangiocarcinoma Foundation and a 16-year survivor of the disease [1].
According to reports released in March 2026, these nanoparticles allow physicians to be more aggressive with gene therapies while minimizing damage to healthy tissue [2, 3]. The system leverages the natural properties of milk-derived components to bypass the body's immune defenses and reach the tumor site [3].
This approach represents a shift toward bio-inspired delivery systems in oncology. By using naturally occurring substances to house synthetic gene therapies, the researchers hope to reduce the toxicity often associated with systemic cancer treatments [2].
“Researchers have developed milk-derived nanoparticles that can deliver gene-therapy payloads directly to cholangiocarcinoma tumors.”
The use of milk-derived nanoparticles suggests a move toward 'biomimetic' drug delivery, where natural substances are used to trick the immune system into accepting foreign therapeutic payloads. If successful, this could provide a blueprint for treating other rare, hard-to-reach cancers that are currently resistant to traditional chemotherapy or systemic gene therapy.
